Form 4: Seres Therapeutics Insider Trades: Henn Acquires, Sells Stock

Matthew R. Henn, Chief Scientific Officer and EVP of Seres Therapeutics, Inc., engaged in transactions involving the acquisition and sale of company common stock, primarily related to tax obligations from vested restricted stock units.

Summary

• Matthew R. Henn, Chief Scientific Officer and EVP of Seres Therapeutics, Inc., acquired 238 shares of common stock on May 15, 2026, as part of a restricted stock unit vesting.
• On May 18, 2026, Henn sold 77 shares of common stock at $7.53 per share.
• These sales were executed under a Rule 10b5-1 trading plan established on April 13, 2023, intended to cover tax liabilities arising from the vesting of restricted stock units.
• Following these transactions, Henn beneficially owns 7,838 shares of Seres Therapeutics common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it details routine insider transactions related to compensation and tax obligations rather than significant strategic shifts or performance indicators.

Positives

• Acquisition of 238 shares of common stock through restricted stock unit vesting, indicating continued equity ownership.
• The transactions were conducted under a pre-established Rule 10b5-1 plan, demonstrating adherence to compliance and risk management protocols.
• The sale of 77 shares was specifically to cover tax obligations, a common and expected event for equity compensation.

Negatives

• Sale of 77 shares of common stock, reducing the reporting person's direct holdings.

Risks

• The vesting and settlement of restricted stock units, while a positive indicator of compensation, can lead to taxable events and subsequent stock sales.
• Reliance on Rule 10b5-1 plans, while compliant, still involves the disposal of company stock.

Future Outlook

The filing does not contain forward-looking statements or guidance. It reports on past transactions.

Management Comments

• The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on April 13, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.
• Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
• The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The specific details here, including the use of a Rule 10b5-1 plan for tax coverage, are common practices within the biotechnology and pharmaceutical sectors where equity-based compensation is prevalent.

Stakeholder Impact

• Shareholders: The transactions are routine and executed under a pre-defined plan, suggesting minimal immediate impact on share price due to these specific trades. However, any insider selling can be perceived negatively if not contextualized.
• Employees: The filing highlights the use of equity compensation and its associated tax implications, a common aspect of employee benefits in the industry.
• Management: Demonstrates adherence to disclosure requirements and responsible management of equity compensation.

Next Steps

• Continued vesting and settlement of remaining restricted stock units in 12 equal quarterly installments.
• Potential future sales under the Rule 10b5-1 plan to cover ongoing tax obligations.

Key Dates

Keywords

Form 4, Insider Trading, Seres Therapeutics, MCRB, Matthew R. Henn, Restricted Stock Units, Rule 10b5-1, Stock Vesting, SEC Filing